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Objectives: To perform a cost-effectiveness analysis and to identify
the cost-effectiveness affordability levels for a newborn universal vac-
cination program against hepatitis B virus (HBV) in Vietnam.
Methods: By using a Markov model, we simulated a Vietnamese birth
cohort using 1,639,000 newborns in 2002 and estimated the incremen-
tal cost-effectiveness ratios for quality-adjusted life-year gained fol-
lowing universal newborn HBV vaccination. Two types of analyses
were performed, including and excluding expenditures on the treat-
ment of chronic hepatitis B and its complications. We used Monte Carlo
simulations to examine cost-effectiveness acceptability and affordabil-
ity from the payer’s perspective and constructed a cost-effectiveness
affordability curve to assess the costs and health effects of the




oi:10.1016/j.vhri.2012.03.007iveness ratio per quality-adjusted life-year gained was US $3.77, much
ower than the 2002 per-capita gross domestic product of US $440. Vac-
ination could potentially be affordable starting at a US $2.1 million
udget. At the cost-effectiveness threshold of US $3.77 per quality-
djusted life-year and an annual budget of US $5.9 million, the proba-
ility that vaccination will be both cost-effective and affordable was
1%. Conclusions: Universal newborn HBV vaccination is highly cost-
ffective in Vietnam. In low-income, high-endemic countries, where
unds are limited and the economic results are uncertain, our findings
n the cost-effectiveness affordability options may assist decision
akers in proper health investments.
eywords: acceptability, affordability, cost-effectiveness, incremental
ost-effectiveness ratio, quality-adjusted life-year.vaccination reduced the carrier rate by 58% at a cost of US $42 per Copyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The hepatitis B virus (HBV) is one of the most prevalent blood-
borne viruses worldwide and is a major cause of chronic liver
diseases and hepatocellular carcinoma [1,2]. It is an important
public health problem for developing countries where the en-
demicity is generally high. Currently, about 350 million people
worldwide are chronic HBV carriers, as demonstrated by the
presence of hepatitis B surface antigen for more than 6 months
[3]. These individuals are at a much higher risk of liver damage;
15% to 40% of the infected patients eventually develop cirrhosis,
liver failure, or hepatocellular carcinoma, contributing to more
than 1 million deaths annually [1,4,5]. Epidemiological studies
have reported that the prevalence of chronic hepatitis B (CHB)
surface antigen carriers is between 8.8% and 20.5% across dif-
ferent populations and regions in Vietnam [6,7]. With a popula-
tion of 86 million in 2010, there would be more than 7.5 million
Conflicts of interest: The authors have indicated that they hav
* Address correspondence to: Hong Anh T. Tu, Unit of PharmacoE
niversity of Groningen, Groningen, The Netherlands.
E-mail: h.a.tu@rug.nl.
212-1099/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.people at risk of premature death due to HBV infections in
Vietnam.
Universal newborn HBV vaccination could be a feasible and
effective solution for preventing HBV infection and a cost-effective
prevention in the developing world [8,9]. In Vietnam, hepatitis B
vaccine was first introduced into the Expanded Program of Immu-
nization in 1997, but universal HBV vaccination was not completed
until mid-2003 with the support from the Global Alliance for Vac-
cines and Immunizations starting in 2002 [10]. To date, data are
lacking regarding the impact of universal newborn vaccination in
Vietnam from a health-economic perspective. While cost-effec-
tiveness analyses of universal HBV vaccination have been exten-
sively performed for many developed countries, such analyses are
still scarce for the developing world [9].
To aid allocation decisions on scarce health care resources, it is
important to assess the cost-effectiveness of any large-scale pre-
vention programs, which require substantial resources. In this ar-
conflicts of interest with regard to the content of this article.
iology and PharmacoEconomics (PE2), Department of Pharmacy,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
8 V A L U E I N H E A L T H R E G I O N A L I S S U E S 1 ( 2 0 1 2 ) 7 – 1 4Fig. 1 – Decision analytic model for estimating the cost-effectiveness of universal hepatitis B vaccination in Vietnam. CC,
compensated cirrhosis; CHB, chronic hepatitis B; DC, decompensated cirrhosis; HbsAg, hepatitis B surface antigen; HCC,
hepatocellular carcinoma.
9V A L U E I N H E A L T H R E G I O N A L I S S U E S 1 ( 2 0 1 2 ) 7 – 1 4ticle, we estimated the cost-effectiveness of the current HBV vac-
cination program in Vietnam. In addition, cost-effectiveness
affordability curves were constructed to estimate the budget im-
pact on the vaccination program.
Methods
Modeling approach
We designed a decision analytic model to estimate the cost-effec-
Table 1 – Base-case estimates and corresponding distribut
Parameter Base-case estimate
Newborn immunization against HBV
HBV prevalence (%) 14.70
Vaccine coverage (%) 70.00
Vaccine efficacy (%) 84.00
Vaccine wastage (%) 12.50
Immunization cost/child (US $)* 4.50
Disease progression
Outcome from chronic hepatitis B
Resolution 0.006183
Chronic hepatitis B #†
Compensated cirrhosis 0.022989
Hepatocellular carcinoma 0.009100
Disease nonrelated deaths Life table





Disease nonrelated deaths Life table




Outcome from hepatocellular carcinoma
Survival 0.088710
Disease-related death #
Cost estimates (US $)
Treatment cost (health care perspective)




Treatment cost (societal perspective)




Discount rate (%) 0 or 3
Quality of life




HBV, hepatitis B virus.
* The hepatitis B vaccine used for newborns in Vietnam was purcha
support from 2002 to 2008. The cost of the vaccine alone was US $1
$ 1.50 (range of US $0.5–3.5) [16,17].
† The hash mark (#) is used in place of the probability express
complement during calculations.tiveness of universal vaccination against HBV compared with novaccination. A Markov model simulating disease progression was
linked to a decision tree (Fig. 1). The analyses were performed by
using the simulation software TreeAge Pro, version 2009.
In the model we focused only on CHB infections because
chronic infections comprise the largest burden of the disease and
published clinical data on acute and fulminant stages are cur-
rently lacking for Vietnam. The Vietnamese birth cohort of 2002
was selected because universal vaccination against HBV was com-
pleted in mid-2003; thus, we can compare the impact before and
after universal HBV vaccination. Type 1 mortality was assumed
(i.e., everyone lives to the life expectancy, which is 75 years in







Gamma (26.56, 4295.75) [18–20]
Gamma (32.98, 11,434.66) [21–25]
Gamma (10.27, 1128.91) [18,20–22,24,26–29]
Beta [30]
Gamma (58.66, 848.48) [31,32]
Gamma (5.72, 354.72) [32]
Gamma (11.04, 333.05) [3,23,33]
Beta [30]
None [34]
Gamma (39.29, 160.21) [35]
Gamma (232.75, 2623.75) [36,37]
Gamma (535.2326; 1.98155) Data available











hrough Global Alliance for Vaccines and Immunizations’s financial
7]. Including the administration costs, the full cost per dose was US




ion foVietnam). Each Markov cycle was defined as 1 year. The Markov
g
G, life
10 V A L U E I N H E A L T H R E G I O N A L I S S U E S 1 ( 2 0 1 2 ) 7 – 1 4health states used in the model were alive, immunity, CHB, com-




The transition probabilities used in the model represent the nat-
ural course of CHB infections and were obtained from interna-
tional literature (through PubMed), particularly from studies in
high-endemic Asian countries where the epidemiology of hepati-
tis B infections is more similar to that of the Vietnamese situation
(Table 1). When there were two or more studies reporting esti-
mates for a particular transition probability, we combined the out-
comes of the studies by using a random effect model to account for
possible heterogeneity [41].
Other parameters (hepatitis B surface antigen carrier preva-
lence, vaccine coverage, vaccine efficacy, and vaccine wastage) are
also presented in Table 1.
Cost estimates
The cost-effectiveness analysis was performed from societal,
health care, and payer’s perspectives. For the societal perspective,
we included direct medical costs (vaccination cost and the averted
costs of treatment for CHB infections), direct nonmedical costs
(travel, meals, and lodging), and indirect costs (productivity loss).
For the health care perspective, only direct medical costs were
included. For the payer’s perspective, where the Vietnamese gov-
ernment or international organizations are the main payers for
vaccination programs, we included only the vaccination cost
(Table 1).
Treatment cost of CHB and its related progressions was taken
from a previous cost-of-illness study we conducted for Vietnam (data
are available upon request). All costs were reported in US $ (US $1
17,803 VND [42]) and adjusted for inflation by using the country’s
ross domestic product deflators (Table 1).
Quality of life
Because of a lack of data on specific quality-of-life estimates for
Vietnam, quality-of-life estimates were based on various interna-
Table 2 – Base-case results for vaccination versus no vacci
carrier rate is 14.7%, vaccine coverage is 70%, vaccine effica
Parameter Unvaccina
HBV carrier rate (%)
Discounted expected life-years per person
Discounted QALY gained per person
No. of new infections for the cohort 240,1
No. of primary liver cancer cases 2,1
No. of premature deaths 2,3
Lifetime cost incurred from societal perspective
(US $) per person
1,1
Lifetime cost incurred from health care perspective
(US $) per person
9
Cost incurred from payer’s perspective (US $) per
person
ICER per LYG (US $) from payer’s perspective
ICER per QALY gained (US $) from payer’s
perspective
Cost of preventing a HBV carrier
Total vaccination cost of birth cohort (US $)
HBV, hepatitis B virus; ICER, incremental cost-effectiveness ratio; LYtional sources (Table 1).Other assumptions
In the model we made several assumptions: 1) all CHB infections
occurred in the first year of life, 2) the mortality and losses of
quality-adjusted life-year (QALY) and life-years gained that were
due to acute hepatitis B infections were ignored, 3) the simulation
continued until 99.9% of the cohort had deceased, and (iv) the
hepatitis B unrelated death rate was based on the age-specific
mortality of the Vietnamese population [30]. In the absence of 2002
age-specific mortality rates, we used the rates from 2006 assuming
that mortality rates remained constant between 2002 and 2006.
Sensitivity analysis
To evaluate parameter uncertainties, we conducted univariate sensitiv-
ity analyses (results from only the payer’s perspective are shown) and
probabilistic sensitivity analyses for all the three perspectives. For the
latter, we conducted 5000 Monte Carlo simulations. Distributions asso-
ciatedwith inputparametersareshowninTable1 [43].Theresultswere
subsequently presented in a cost-effectiveness acceptability curve
(CEAC) from the payer’s perspective only. We then evaluated affordabil-
ity on the basis of joint distribution of simulated incremental costs and
health gains of HBV vaccination. Affordability analysis was done with






Fig. 2 – Results of univariate sensitivity analyses showing
the ranges of ICERs for universal newborn HBV vaccination
compared with no vaccination in Vietnam (payer’s
perspective). HBV, hepatitis B virus; ICERs, incremental
n strategies against HBV for newborns where the HBV
s 84%, vaccine wastage is 12.5%, and discount rate is 3%.
























10.00cost-effectiveness ratios; QALY, quality-adjusted life-year.
uali
11V A L U E I N H E A L T H R E G I O N A L I S S U E S 1 ( 2 0 1 2 ) 7 – 1 4the assumption that vaccination programs for infants were indivisible,
which means it cannot be done for only a fraction of infants be-
cause in Vietnam universal hepatitis B vaccination is for every
child. By using the theory and methodology described by Sendi
and Briggs [44], we generated a CEAC by capturing the points in the
cost-effectiveness plane under the horizontal lines representing
different budget levels.
Outcome measurement
Life-years gained, QALY, and incremental cost-effectiveness ra-
tios per life-year gained and per QALY for different scenarios (vac-
Fig. 3 – A total of 5000 Monte Carlo simulations of incremen
plane comparing vaccination versus no vaccination. QALY, qcination vs. no vaccination) were calculated.Results
Results of the base-case analyses comparing universal HBV vacci-
nation with no vaccination are presented in Table 2. Vaccination is
highly cost-effective from the payer’s perspective and cost-saving
from societal and health care perspectives.
Univariate sensitivity analyses (shown only for the payer’s per-
spective) showed that incremental cost-effectiveness ratios were
most sensitive to vaccine price and HBV prevalence (Fig. 2). Prob-
abilistic sensitivity analyses results are demonstrated on cost-ef-
fective planes, confirming that universal vaccination dominates
st-effectiveness ratios plotted on a cost-effectiveness
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rived, reporting that at the base-case threshold (US $3.77 per
QALY), the cost-effectiveness probability for the vaccination pro-
gram was 51%. At the willingness-to-pay (WTP) threshold of US
$18 per QALY, the cost-effectiveness probability reached 100%, but
it decreased to 0% when the WTP threshold was less than US $1
per QALY (Fig. 4).
Furthermore, affordability curves were generated to explain
the impact of financial resources on the vaccination program. We
explicitly assessed the impact of the budget on vaccination alone;
thus, all affordability and cost-effectiveness affordability analyses
were evaluated from the payer’s perspective. The results indicated
Fig. 4 – Cost-effectiveness (C–E) acceptability curve showing
that the probability of universal newborn vaccination
against HBV in Vietnam is cost-effective at different cost-
effective threshold values (payer’s perspective). HBV,
hepatitis B virus; QALY, quality-adjusted life-year.
Fig. 5 – Affordability curve showing the impact of financial
resources on the universal newborn HBV vaccination
program in Vietnam (payer’s perspective). HBV, hepatitis Bcvirus.that vaccination would not be affordable when the budget is less
than US $2 million but always implementable when the budget
exceeds US $13 million (Fig. 5). For the base-case at the US $5.9
million budget per year (Table 2), the probability for the program
being affordable was only 26% because of the uncertainties sur-
rounding the program cost.
Combining the CEAC and the affordability curve, the cost-ef-
fectiveness affordability curve presented various scenarios for a
vaccination program being both cost-effective and affordable at
different cost-effective threshold values and budgets (Fig. 6). If the
budget is less than US $2 million, the probability for the vaccina-
tion program to be cost-effective and affordable is 0%, regardless
of the WTP threshold. In the base-case scenario with a cost-effec-
tive threshold of US $3.77 per QALY and the US $5.9 million budget,
the probability was 21%. The vaccination program would be 100%
cost-effective and affordable when the budget reaches US $13 mil-
lion and the WTP threshold reaches US $18 per QALY.
Discussion
The results from the base-case analyses showed that universal
newborn HBV vaccination could reduce the HBV carrier rate by
60%. Using the World Health Organization’s criteria for cost-
effectiveness [45], our analyses suggest that HBV vaccination in
Vietnam is highly cost-effective from the payer’s perspective
and a cost-saving intervention from both societal and health
care perspectives. The incremental cost-effectiveness ratio was
only US $3.77 per QALY, which is much lower than 3 Vietnam-
ese per-capita gross domestic product in 2002 [46]. The cost-
effectiveness of the program was most sensitive to vaccine price
and HBV prevalence.
At the country’s per-capita GDP of US $440 in 2002 [46] and the
ssumed cost of US $4.5 per fully immunized child, vaccination
emained an acceptable and affordable option even for a Vietnam-
se household to pay out of pocket. However, with an annual birth
Fig. 6 – Cost-effectiveness (C–E) and affordability curve
presenting various scenarios for universal newborn HBV
vaccination in Vietnam being both cost-effective and
affordable at different cost-effective threshold values and
budgets (payer’s perspective). HBV, hepatitis B virus; QALY,
quality-adjusted life-year.ohort of 1,639,000, HBV vaccination could become a large invest-
13V A L U E I N H E A L T H R E G I O N A L I S S U E S 1 ( 2 0 1 2 ) 7 – 1 4ment for the Vietnamese government. Thus, the cost of universal
vaccination poses a heavy financial burden when the Global Alli-
ance for Vaccines and Immunizations’s support for Vietnam in the
Expanded Program of Immunization is terminated. This financial
implication should prompt the Vietnamese health decision mak-
ers to access the processes involved in setting priorities and allo-
cating limited resources among different childhood vaccination
programs. In this context, the importance of examining affordabil-
ity and cost-effectiveness of large-scale health programs should
be taken in consideration. The strength of affordability analysis is
its accountability of uncertainties of health and effects by running
probabilistic sensitivity analyses. It assists policymakers to esti-
mate the affordable probability of a vaccination program under a
specific budget and to look for external resources if the govern-
ment cannot finance the program itself. In details, the affordabil-
ity curve estimated that the newborn HBV vaccination in Viet-
nam could start as low as US $2,100,000 but becomes 100% cost-
effective and affordable with an annual budget of at least US $13
million. Even at this maximum level of investment, the program
cost is extremely modest in comparison to the treatment costs
of CHB infections in Vietnam. In addition, vaccination will grad-
ually reduce HBV prevalence in Vietnam. Therefore, continuing
the vaccination program appears to be a wise health invest-
ment. Using affordability as a tool to forecast the needed budget
also aids the Vietnamese government in the application for fur-
ther financial support from the Global Alliance for Vaccines and
Immunizations.
Naturally, our study has a few limitations. First, we applied a
simple static Markov model of the disease instead of a dynamic
model. Because of the lack of data and information, we opted to
focus only on the chronic part of the hepatitis B infection and
ignored the acute and fulminant stages. However, morbidity from
these clinical presentations was short-lasting and mortality con-
stituted only a small proportion of hepatitis B–related deaths, but
their inclusion in our model would likely make HBV vaccination
even more cost-effective. Second, because of an absence of pub-
lished epidemiological data on hepatitis B in Vietnam, we used
published data from other countries in the region where extensive
research on the disease had been conducted [19,25,28,29,35], or
data from the Western world (in the cases where no data were
available at all). This is justified because disease progression rates
appear to be stable across populations. Third, we did not have the
age-specific disease progression rate and we assumed the same
prevalence rate for all age groups. This might underestimate the
number of infections that would occur in this birth cohort and that
current prevalence is a rough estimate for infections that might
occur to the population. Fourth, the study did not take into ac-
count the indirect herd-immunity effects; doing so again would
likely make HBV vaccination more cost-effective.
As the first cost-effectiveness study on universal newborn
vaccination in Vietnam, the outcomes are very encouraging and
informative. The results might assist policymakers in motivat-
ing the continued support for universal HBV vaccination. Our
findings will also be informative for health-policy decisions in
other high-endemic countries of HBV prevalence. In addition,
our study demonstrated that next to conducting cost-effective-
ness analysis of large-scale intervention programs, cost-effec-
tiveness affordability curves can be used for resource planning
of health interventions, especially for new and underused vac-
cines. To fully evaluate the impact of HBV vaccination in Viet-
nam, future studies applying dynamic models of HBV infection
to account for herd immunity and acute and fulminant stages of
the disease are recommended.
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